A vaccine that uses the same methods as Pfizer products to prevent people from becoming seriously ill with Covid-19 is one step closer to being approved for use in Australia.
The US medical company Moderna has been granted a tentative decision on the coronavirus vaccine Elasomeran, the Therapeutic Goods Department said Thursday.
The interim decision means that Moderna can apply for interim registration of the vaccine in the drug register kept by the Australian authorities.
In other words, the vaccine has cleared an important hurdle to approval.
“Moderna will soon submit an application for provisional registration,” TGA said in a statement.
“Importantly, registration and supply in Australia will only begin if the vaccine is approved by TGA to be safe and effective.”
Australia has already ordered 25 million Moderna vaccines, 10 million this year and the rest next year.
The dose expected to be ready by 2022 will be an updated booster shot to process new variants of the virus.
Both Moderna and Pfizer use state-of-the-art science known as mRNA for coronavirus vaccines.
The acronym “m” stands for messenger, and RNA is ribonucleic acid found in human cells.
Vaccines use “messenger” information to teach cells how to make spiked proteins. Peplomers are recognized by the body as foreign bodies and encourage them to build an immune response.
If the vaccinated person is infected with the coronavirus, the reaction is useful because the body already knows how to protect it from the coronavirus.
According to the TGA, the Moderna vaccine will be considered for use by individuals over the age of 12.
Currently used in several other countries.